Company Information

    TScan Therapeutics was founded on January 2018. The company is based in Boston, MA, USA . The number of employees in TScan Therapeutics is less than 50. Tscan therapeutics is an experienced group of scientists, development specialists, and other leaders driving a cutting edge platform
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          TScan Therapeutics has received 4 rounds of venture funding. The total funding amount is around $137.5M. Last venture funding round was $100M, announced on January, 2021.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        TScan Therapeutics - Blog

                          • TScan Therapeutics to Participate in Upcoming Investor Conferences

                          • WALTHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participateThe post TScan Therapeutics to Participate in Upcoming Investor Conferences appeared first on TScan Therapeutics.
                          • TScan Therapeutics Appoints Heather Savelle as Vice President, Investor Relations

                          • WALTHAM, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of HeatherThe post TScan Therapeutics Appoints Heather Savelle as Vice President, Investor Relations appeared first on TScan Therapeutics.
                          • TScan Therapeutics to Participate in the Chardan 5th Annual Genetic Medicines Conference

                          • WALTHAM, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David Southwell, PresidentThe post TScan Therapeutics to Participate in the Chardan 5th Annual Genetic Medicines Conference appeared first on TScan Therapeutics.
                          • TScan Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

                          • WALTHAM, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David Southwell, PresidentThe post TScan Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference appeared first on TScan Therapeutics.
                          • TScan Therapeutics to Present Discovery of T Cell Targets for COVID-19 at the Cell-Mediated Therapies for Infectious Disease Summit

                          • Company advancing research of a next-generation vaccine construct for SARS-CoV-2 using T cell target discoveries WALTHAM, Mass., July 21, 2021 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered TThe post TScan Therapeutics to Present Discovery of T Cell Targets for COVID-19 at the Cell-Mediated Therapies for Infectious Disease Summit appeared first on TScan Therapeutics.
                          • TScan Therapeutics, Inc. Announces Pricing of Initial Public Offering

                          • WALTHAM, Mass., July 15, 2021 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (TScan), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of its initial publicThe post TScan Therapeutics, Inc. Announces Pricing of Initial Public Offering appeared first on TScan Therapeutics.

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *